상세정보
- 상세정보
Cancer Immunotherapies Solid Tumors and Hematologic Malignancies [electronic resource]
Hays, Priya
- 책이미지
-
- 도서 상세정보
- 서평쓰기
| 자료유형 | 단행본 |
|---|---|
| 개인저자 | Hays, Priya.,editor. |
| 단체저자명 | SpringerLink (Online service). |
| 서명/저자사항 | Cancer Immunotherapies [electronic resource] : Solid Tumors and Hematologic Malignancies / edited by Priya Hays. |
| 판사항 | 1st ed. 2022. |
| 형태사항 | XVI, 315 p. 32 illus., 31 illus. in color:online resource. |
| 총서사항 | Cancer Treatment and Research=2509-8497 ;183 |
| 총서부출표목 | Cancer Treatment and Research,183 |
| 기본자료 저록 | Springer Nature eBook |
| 기타형태 저록 | Printed edition:9783030963750Printed edition:9783030963774Printed edition:9783030963781 |
| ISBN | 9783030963767 |
| 기타표준부호 | 10.1007/978-3-030-96376-7 |
| 내용주기 | Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies. |
| 요약 | This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies. |
| 일반주제명 | Oncology. Hematology. Genetics. Genomics. Oncology. Hematology. Genetics. Genomics. |
| 바로가기 | URL |